Zygmont Chester Stanley III 4
4 · REVELATION BIOSCIENCES, INC. · Filed May 1, 2026
Research Summary
AI-generated summary of this filing
Revelation Biosciences (REVB) CFO Chester Zygmont Sells 13,285 Shares
What Happened
Chester S. Zygmont III, Chief Financial Officer of Revelation Biosciences (REVB), had 13,285 shares sold on April 30, 2026 to satisfy required tax withholding related to vested restricted stock. The sale generated approximately $14,614 in proceeds based on a weighted average price of $1.10 per share (individual sale prices ranged $1.09–$1.13).
Key Details
- Transaction date: 2026-04-30; Form 4 filed 2026-05-01 (appears timely).
- Transaction type: Code F — shares sold by the issuer to satisfy tax withholding upon vesting (mandatory).
- Shares sold: 13,285; weighted avg price reported $1.10; reported range $1.09–$1.13.
- Proceeds: ~$14,614.
- Shares owned after transaction: Not specified in this filing.
- Relevant footnotes: F1 (mandatory tax-withholding sale), F2 (price is weighted avg; multiple sale prices disclosed), F3 and F4 note some shares are held in entities (The Zygmont Family Trust and Czeslaw Capital Fund, LLC) for which Zygmont is trustee/sole manager.
Context
This was a mandatory, routine tax-withholding sale tied to restricted stock vesting (not an opportunistic open-market sale). Such F-code transactions typically reflect administrative requirements rather than a signal about the insider’s view of company prospects.
Insider Transaction Report
- Tax Payment
Common Stock
[F1][F2][F3]2026-04-30$1.10/sh−13,285$14,614→ 92,063 total(indirect: By Trust)
- 2(indirect: By LLC)
Common Stock
[F4]
Footnotes (4)
- [F1]Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.
- [F4]Shares are held by Czeslaw Capital Fund, LLC. Chester S Zygmont III is the sole manager of Czeslaw Capital Fund, LLC.